ycopene with milk and soy-based
proteins to produce a much smaller, and more bio-available molecule. The
early studies have shown that Ateronon can inhibit the oxidation of low
density lipoprotein (LDL) cholesterol, which can put people at risk of
suffereing heart attacks and stroke, to almost zero within eight weeks.
An estimated 17.5 million people died from heart and circulatory diseases
in 2005, representing 30% of all global deaths. Of these deaths, an estimated
7.6 million were due to coronary heart disease and 5.7 million were due to
More than 117,000 people die each year in the UK from coronary heart
disease. It accounts for one in five deaths in men and one in six deaths in
The four million people who take statins to help lower their cholesterol
and chances of suffering a heart attack or stroke could benefit from using
Ateronon. The product can be taken alongside statins.
Although cholesterol does put people at risk of suffering a heart attack
or stroke, half of all heart attacks and three quarters of all strokes occur
in people who do not have raised cholesterol.
Large scale studies of Ateronon are being undertaken at Addenbrookes
Hospital, Cambridge, and at Harvard Medical School, in the expectation that
they will demonstrate that the reduction of LDL oxidation is translated into
improved heart and circulatory health - and improved survival rates.
The study was built on research originally carried out by the
multi-national food giant Nestle, who were looking for a way to capture the
therapeutic benefits of the tomato-derived compound lycopene.
After its launch to doctors this month, Ateronon will be made available
direct to consumers through high street pharmacists from July onwards.
Dr Gunter Schmidt, a biologist and chief executive of CTL, said he was
confident that once doctors had observed Page: 1 2 3 Related medicine technology :1
. Many Heart Attack Patients Dont Get Best Emergency Treatment2
. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management3
. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?4
. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September5
. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development6
. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue7
. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer8
. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure9
. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care10
. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results11
. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials